StockData
COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Hemab Therapeutics Holdings, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$32.09+2.02 (+6.72%)

Close on Oct 19, 2026

Market cap
$966.27M
P/E (TTM)
–
Dividend yield
–

SEC filings

7 of Hemab Therapeutics's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KSep 24, 2026Sep 24, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 11, 2026SEC EDGAR
Current report8-KAug 11, 2026Aug 11, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 21, 2026SEC EDGAR
Current report8-KMay 21, 2026May 21, 2026SEC EDGAR
Current report8-KMay 8, 2026May 11, 2026SEC EDGAR
Current report8-KMay 4, 2026May 4, 2026SEC EDGAR